| 1 |
27790745 | N-Ras mutation in vemurafenib-associated expanding melanocytic nevus. | 2017 May |
1 |
| 2 |
26460303 | Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. | 2015 Dec 1 |
1 |
| 3 |
26608120 | Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. | 2015 Dec |
2 |
| 4 |
24422853 | Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. | 2014 May |
1 |
| 5 |
24589925 | Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. | 2014 May |
1 |
| 6 |
25063807 | Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells. | 2014 Oct 3 |
5 |
| 7 |
23490205 | Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. | 2013 Jul |
2 |
| 8 |
23569304 | Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. | 2013 May 10 |
1 |
| 9 |
22256804 | RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. | 2012 Jan 19 |
1 |
| 10 |
22395615 | Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. | 2012 Mar 6 |
1 |
| 11 |
28809522 | Vemurafenib Therapy and BRAF and NRAS Genotype | 2012 |
2 |
| 12 |
22194965 | Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. | 2011 |
2 |
| 13 |
21107323 | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. | 2010 Dec 16 |
2 |